Oncology and Hematology
321-336 of 790
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
- MinuteCE®
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
1.00 program creditKomal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Giuseppe Curigliano, MD, PhD
Alexandria May, PharmD, BCPS
Angela Waanders, MD, MPH, MS
Ashley S. Margol, MD, MS
Charles Turck, PharmD, BCPS, BCCCP
David Dingli, MD, PhD
Charles Turck, PharmD, BCPS, BCCCP
Hana Safah, MD
Timothy Kubal, MD
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Jennifer Caudle, DO, FACOFP
Catherine Broome, MD
Peter Buch, MD, FACG, AGAF, FACP
Aasma Shaukat, MD, MPH
Brian P. McDonough, MD, FAAFP
Vinod Pullarkat, MD
